Urinary Exosomal Biomarkers of Thyroglobulin and Galectin-3 for Prognosis and Follow-up in Patients of Thyroid Cancer
Launched by NATIONAL TAIWAN UNIVERSITY HOSPITAL · Jun 24, 2021
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at specific markers in urine that may help doctors predict how well patients with thyroid cancer are doing after treatment. The study focuses on patients who have had surgery to remove their thyroid and possibly received radioactive iodine therapy. So far, 73 patients have joined the study, and the researchers plan to include 30 more. They are particularly interested in understanding any differences between two types of thyroid cancer: papillary and follicular.
To be eligible for this study, participants should have a clear diagnosis of papillary, follicular, or anaplastic thyroid cancer and be in the follow-up phase after surgery. Unfortunately, those who have unclear diagnoses cannot participate. If someone joins the study, they can expect to have their urine tested regularly to check for certain markers, which may provide important information about their health and help guide their ongoing care.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • diagnosed patients with thyroid papillary, follicular and anaplastic thyroid cancer, post-operation follow up
- Exclusion Criteria:
- • unclearly diagnosed patients with thyroid papillary, follicular and anaplastic thyroid cancer
About National Taiwan University Hospital
National Taiwan University Hospital (NTUH) is a leading medical institution renowned for its commitment to advancing healthcare through innovative research and clinical trials. As a pioneer in medical education and patient care in Taiwan, NTUH integrates cutting-edge technology with comprehensive clinical expertise to facilitate groundbreaking studies across various medical fields. The hospital’s dedicated research team collaborates with local and international partners to enhance the understanding of diseases and improve treatment outcomes. By prioritizing patient safety and ethical standards, NTUH strives to contribute to the global medical community and foster advancements in healthcare practices.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Taipei, , Taiwan
Patients applied
Trial Officials
CHIH-YUAN WANG, Doctor
Principal Investigator
Department of Internal Medicine, National Taiwan University Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials